Molecular Formula: C29H41F2N5O
Molecular weight: 513.7 g/mol
CAS No: 376348-65-1
ATC Code: J05AX09
Drug Class: HIV entry and fusion inhibitors
General Properties:
Maraviroc is a monocarboxylic acid amide obtained by formal condensation of the carboxy group of 4,4-difluorocyclohexanecarboxylic acid and the primary amino group of (1S)-3-[(3-exo)-3-(3-isopropyl-5-methyl-4H-1,2,4-triazol-4-yl)-8-azabicyclo[3.2.1]oct-8-yl]-1-phenylpropylamine. An antiretroviral drug, it prevents the interaction of HIV-1 gp120 and chemokine receptor 5 (CCR5) necessary for CCR5-tropic HIV-1 to enter cells. It has a role as an antiviral drug, a chemokine receptor 5 antagonist and a HIV fusion inhibitor. It is an azabicycloalkane, an organofluorine compound, a member of triazoles and a monocarboxylic acid amide.
Maraviroc (brand name: Selzentry) is a prescription medicine approved by the U.S. Food and Drug Administration (FDA) for the treatment of HIV infection in adults and children weighing at least 4.4 lb (2 kg). Maraviroc is always used in combination with other HIV medicines.
Maraviroc should not be used in premature newborns or children weighing less than 4.4 lb (2 kg).
Maraviroc should only be used in people whose strain of HIV uses the CCR5coreceptor. Maraviroc is not recommended for people whose HIV uses the CXCR4 coreceptor or both the CCR5 and CXCR4 coreceptors. Your health care provider will do a blood test to see whether your HIV uses only the CCR5 coreceptor.
Maraviroc is a CCR5 Co-receptor Antagonist. The mechanism of action of maraviroc is as a Chemokine Co-receptor 5 Antagonist.
Indication:
Maraviroc is used in combination with other medicines, in the treatment of the infection caused by the human immunodeficiency virus (HIV). HIV is the virus that causes acquired immune deficiency syndrome (AIDS). This medicine is usually given to patients who have received HIV treatment in the past.
